Q-omics provides the consensus-scored DEFB109A profile across patient tissues and cancer cell-line models. DEFB109A expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, DEFB109A is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, DEFB109A RNA expression shows 9,732 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, HNSC, and TGCT as cancer lineages where DEFB109A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB109A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB109A survival associations across molecular data types. DEFB109A RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB109A RNA expression–survival associations across cancer types. High DEFB109A expression shows unfavorable associations in CESC, STAD, KIRP and ESCA, but favorable associations in LGG and ACC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify CESC as the clearest survival context for DEFB109A RNA expression.
This table summarizes DEFB109A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB109A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB109A shows lower tumor expression in HNSC, THCA, KICH and BRCA and higher tumor expression in CHOL. The HNSC box plot shows higher DEFB109A RNA expression in normal versus tumor tissue (log2 FC = −0.108, t-test p = .005).
This table shows molecular features associated with DEFB109A in patient tissues and cancer cell lines. In patient samples, DEFB109A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
